Fluidigm (NASDAQ:FLDM) announced its quarterly earnings results on Thursday. The medical research company reported ($0.18) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.07, Morningstar.com reports. Fluidigm had a negative return on equity of 90.07% and a negative net margin of 52.24%. The firm had revenue of $32.33 million during the quarter, compared to analyst estimates of $30.55 million.
NASDAQ:FLDM traded up $0.80 during trading hours on Friday, hitting $9.35. 3,626,242 shares of the stock were exchanged, compared to its average volume of 635,439. Fluidigm has a 52-week low of $4.65 and a 52-week high of $9.76. The company has a current ratio of 1.85, a quick ratio of 1.45 and a debt-to-equity ratio of 7.56. The firm has a market cap of $367.64 million, a P/E ratio of -11.69 and a beta of 2.29.
FLDM has been the subject of several recent analyst reports. Zacks Investment Research lowered Fluidigm from a “hold” rating to a “sell” rating in a research note on Wednesday, January 16th. ValuEngine upgraded Fluidigm from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. BidaskClub upgraded Fluidigm from a “hold” rating to a “buy” rating in a research note on Thursday, December 27th. Janney Montgomery Scott upgraded Fluidigm from a “neutral” rating to a “buy” rating in a research note on Thursday, January 3rd. Finally, Piper Jaffray Companies upgraded Fluidigm from a “neutral” rating to an “overweight” rating in a research note on Friday, November 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. Fluidigm presently has an average rating of “Hold” and a consensus target price of $9.25.
A number of large investors have recently bought and sold shares of the business. BlackRock Inc. increased its stake in Fluidigm by 9.1% during the 4th quarter. BlackRock Inc. now owns 2,139,878 shares of the medical research company’s stock worth $18,445,000 after buying an additional 178,429 shares in the last quarter. New York State Common Retirement Fund increased its stake in Fluidigm by 189.4% during the 4th quarter. New York State Common Retirement Fund now owns 57,300 shares of the medical research company’s stock worth $494,000 after buying an additional 37,500 shares in the last quarter. Acadian Asset Management LLC increased its stake in Fluidigm by 13.2% during the 4th quarter. Acadian Asset Management LLC now owns 538,749 shares of the medical research company’s stock worth $4,643,000 after buying an additional 62,686 shares in the last quarter. Monarch Partners Asset Management LLC purchased a new stake in Fluidigm during the 4th quarter worth approximately $317,000. Finally, Cookson Peirce & Co. Inc. purchased a new stake in Fluidigm during the 4th quarter worth approximately $536,000. Institutional investors own 98.30% of the company’s stock.
WARNING: This article was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/4138696/fluidigm-fldm-releases-quarterly-earnings-results-beats-estimates-by-0-07-eps.html.
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.
See Also: Stock Symbol
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.